| abstract |
Formula I: [Where m and n are each independently 0 or 1; R 1 and R 2 together with the carbon atom to which they are attached, are one or two hetero groups selected from oxygen, sulfur, —S (O) — and —S (O) 2 — Forming a heterocyclic ring containing atoms; R 3 is —CHF 2 , —CF 3 , —OCHF 2 , —OCF 3 , —SCHF 2 or —SCF 3 ; X is a bond, —CH 2 — or —NH—; A is aryl, cycloalkyl, cycloalkenyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkenyl, which are optionally substituted by one or more identical or different substituents selected from R 4 Substituted with a group; R 4 is hydrogen, amino, thioxo, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, halogen, oxo, thia or hydroxy. ] It has been found that the compounds of the invention, or pharmaceutically acceptable salts, hydrates or solvates thereof, exhibit PDE4 inhibitory activity and may be useful in the treatment of inflammatory diseases and disorders. |